

*Final*

OUTLINE  
VINYL CHLORIDE PRESENTATION

1. Scope of Health Problem: Monomer plants - 2000 workers  
Polymer plants - 6-8000 workers  
Fabricators - over 100,000 workers
2. Economics: Various estimates but in the range  
of \$2 to \$4 billion annually
3. Angiosarcoma Cases Discovered Worldwide to Date: Polymer plants - 11  
Monomer plants - 1  
Fabricators - Not studied
4. Comments on Industry Studies of Health Problems: Acro-osteolitis - BFG (1966)  
Animal studies - Solvay (1970)  
" " - Solvay-ICI (1972-74)  
" " - MCA (in progress)  
Human Effects - Dow (1972)  
" " - Dynamit Nobel (1973)  
" " - MCA (Review Draft circulated)
5. Comments on Trade Association Efforts: MCA, SPI, ORC
6. Effects on Industry Image, PR, and Union Relations
7. Immediate Impact on Industry:  
  
Monomer Producers - led by Dow, Shell, UC & PPG  
Determined to survive (review strategies evolving)  
  
Polymer producers - Still in reactive posture -  
somewhat demoralized  
  
Fabricators - Pushing problems back on  
PVC suppliers.

#### 8. Long Term Impact on Industry:

Major tonnage and revenues will survive  
(95% of tons, 90% of dollars)

Some trivial or optional uses may disappear  
(e.g. latex paints)

Improved control in monomer plants  
(2 to 5% of current value additional investment)

Improved control in polymer plants  
(10 to 50% of current value additional investment)  
(Some polymer plants probably will not survive)

Highly restrictive work practices mandated by law.

Much tighter, DOT, FDA, and EPA regulations.  
(Capital above does not cover these factors.)

Comprehensive medical programs mandated.

1. At least annual, no omissions
2. Lifetime medical surveillance

Workmen's Comp presumption that any liver disease  
is occupational.

#### 9. Ripple Effects - Questions being raised about other tonnage organics

Chlorinated solvents (carbon tet now a claimed carcinogen)  
Fluorocarbons  
TDI

#### 10. Probable Industry Reactions

"Catchup" screening of important products and intermediates.

Voluntary epidemiology studies will multiply.

Strengthened medical programs, IH programs,  
better record keeping.

Companies can no longer afford to conceal adverse  
health information.